Boxing bladder cancer with COX-2-specific inhibition

Cancer Prevention Research

Volumn 4, Issue 10, 2011, Pages 1534-1535

  Kelly, John D ^a   Hall, Emma ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BCG VACCINE; CELECOXIB; CYCLOOXYGENASE 2; IBUPROFEN; NAPROXEN; PLACEBO;

ARTHRITIS; BARRETT ESOPHAGUS; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; EFFECT SIZE; HIGH RISK PATIENT; HUMAN; NON MUSCLE INVASIVE BLADDER CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT CANCER; RISK BENEFIT ANALYSIS; RISK REDUCTION; SHORT SURVEY; TRANSURETHRAL RESECTION; TREATMENT DURATION; TREATMENT OUTCOME;

CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PYRAZOLES; SULFONAMIDES; URINARY BLADDER NEOPLASMS;

EID: 80053899941     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0409     Document Type: Short Survey

References (9)

1. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RKNon-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000;82:1364-69 (Pubitemid 30145360)
2. Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, Kelloff GJ, Hill DL, Seibert KCelecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine- induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000;60:5599-602.
3. Dovedi SJ, Kirby JA, Atkins H, Davies BR, Kelly JD. Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma. Eur Urol 2008;7;96:1384-93.
4. Sabichi AL, Lee JJ, Grossman HB, Liu S, Richmond E, Czerniak BA, et al. A randomized controlled trial of celecoxib to prevent recurrence of non-muscle- invasive bladder cancer. Cancer Prev Res 2011;4:1580-89.
5. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008;117:2104-13. (Pubitemid 351572169)
6. Falk GW, Jankowski J. Chemoprevention and Barrett's esophagus: decisions, decisions. Am J Gastroenterol 2008;103:2443-5.
7. Becker MC, Wang TH, Wisniewski L, Wolski K, Libby P, Lüscher TF, et al. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J 2009;157:606-12.
8. Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU). Coxib and traditional NSAID Trialists' (CNT) Collaboration. Available from: http://www.ctsu.ox.ac.uk/projects/cnt/index-html; accessed 5/22/2011.
9. Chan AT, Sima SS, Zauber AG, Ridker PM, Hawk ET, Bertagnolli MM. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res 2011;4:1172-80.